Donald Trump & Novo Nordisk
11 shared events · Importance 3 · Last updated Apr 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
Donald Trump: Donald Trump>>> announced the expansion of TrumpRx, a key initiative of his administration to lower drug prices for United States>>> consumers.
Novo Nordisk: Novo Nordisk>>> is participating in the TrumpRx program, agreeing to reduce prices on popular GLP-1 weight-loss medications.
Jun 06, 2026 · 8 articles
Business
Donald Trump: Announced tariffs on imported generic drugs in 2028, contributing to stock decline.
Novo Nordisk: Novo Nordisk is the originator of semaglutide; the delay does not directly affect its products but may reduce competition in the short term.
Jul 09, 2026 · 23 articles
Regulatory
Novo Nordisk: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Donald Trump and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard